白蛋白尿变化预测2型糖尿病心血管与肾脏结局:LEADER试验事后分析
LEADER试验事后分析纳入9340例心血管高危的2型糖尿病患者,按基线至1年尿白蛋白肌酐比(UACR)变化分组,评估其与主要心血管不良事件(MACE)及复合肾脏结局的关联。结果显示,UACR降低>30%与MACE及肾脏结局风险显著降低相关,且独立于治疗分组。
要点
- 1年内UACR降低>30%与MACE风险降低18%相关(HR 0.82)。
- 白蛋白尿监测应作为糖尿病管理的重要组成部分。
核心结论
- 第一年内白蛋白尿减少与心血管和肾脏结局减少相关,且独立于治疗。
研究设计与样本
- LEADER试验事后分析,纳入9340例心血管高危的2型糖尿病患者,随机接受利拉鲁肽≤1.8 mg/天或安慰剂加标准治疗3.5-5年。
主要发现
- UACR降低>30%组(n=2928)相比UACR任何升高组(n=4124),MACE的HR为0.82(95%CI 0.71,0.94;P=0.006),复合肾脏结局HR为0.67(95%CI 0.49,0.93;P=0.02)。
- UACR降低30-0%组(n=1218)相比UACR任何升高组,MACE的HR为0.99(95%CI 0.82,1.19;P=0.912),复合肾脏结局HR为0.97(95%CI 0.66,1.43;P=0.881)。
- 结果独立于基线UACR,且在两个治疗组中一致。
临床怎么用
- 在2型糖尿病管理中应定期监测白蛋白尿,UACR降低>30%可作为心血管和肾脏获益的替代指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A post hoc analysis to investigate the association between 1-year changes in albuminuria and subsequent risk of cardiovascular and renal events. RESEARCH DESIGN AND METHODS: LEADER was a randomized trial of liraglutide up to 1.8 mg/day versus placebo added to standard care for 3.5-5 years in 9,340 participants with type 2 diabetes and high cardiovascular risk. We calculated change in urinary albumin-to-creatinine ratio (UACR) from baseline to 1 year in participants with >30% reduction (n = 2,928), 30-0% reduction (n = 1,218), or any increase in UACR (n = 4,124), irrespective of treatment. Using Cox regression, risks of major adverse cardiovascular events (MACE) and a composite nephropathy outcome (from 1 year to end of trial in subgroups by baseline UACR [<30 mg/g, 30-300 mg/g, or ≥300 mg/g]) were assessed. The analysis was adjusted for treatment allocation alone as a fixed factor and for baseline variables associated with cardiovascular and renal outcomes. RESULTS: For MACE, hazard ratios (HRs) for those with >30% and 30-0% UACR reduction were 0.82 (95% CI 0.71, 0.94; P = 0.006) and 0.99 (0.82, 1.19; P = 0.912), respectively, compared with any increase in UACR (reference). For the composite nephropathy outcome, respective HRs were 0.67 (0.49, 0.93; P = 0.02) and 0.97 (0.66, 1.43; P = 0.881). Results were independent of baseline UACR and consistent in both treatment groups. After adjustment, HRs were significant and consistent in >30% reduction subgroups with baseline micro- or macroalbuminuria. CONCLUSIONS: A reduction in albuminuria during the 1st year was associated with fewer cardiovascular and renal outcomes, independent of treatment. Albuminuria monitoring remains an important part of diabetes care, with great unused potential.
引用
- Persson F, Bain SC, Mosenzon O, et al. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 2021. PMID: 33504496. doi:10.2337/dc20-1622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。